Date: 2017-01-06
Type of information: Collaboration agreement
Compound: translational biomarkers for Opdivo® (nivolumab)
Company: BMS (USA - NY) GeneCentric Diagnostics (USA - NC)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism: biomarker
Disease:
Details: * On January 6, 2017, BMS and GeneCentric Diagnostics announced a biomarker research collaboration to explore whether the application of GeneCentric’s Cancer Subtype Platform (CSP™) might be able to identify translational biomarkers for Opdivo® (nivolumab), which may help inform future clinical trials. CSP™ identifies biologic subtypes of cancer through an integrated analysis of tumor genomics. Cancer subtypes can support rational clinical trial design, as biomarkers to identify patient cohorts optimally suited for certain therapeutic compounds, and as companion diagnostics.
Financial terms: GeneCentric announced it has secured equity funding from BMS that will support the clinical development of GeneCentric’s CSP™ and build-out of GeneCentric’s new laboratory in Research Triangle Park.
Latest news:
